·More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1 ·DRD is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe.2,3 ·There is an urgent need for earlier detection of DRD [...]
London, Nov. 11, 2024 (Korea Bizwire) – OPEN Health, a preeminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting services, today announced the upcoming presentation of a collection of research supported by its Scientific Buyout Program. The Scientific Buyout Program initiative allows staff members to “buy out” time from their regular duties to engage in important scientific [...]
SPRING, Texas, Nov. 08, 2024 (Korea Bizwire) – Io Therapeutics, Inc., presented results from studies done in breast, colorectal, and prostate cancer models with the company’s newest anti-cancer compound IRX5010, an agonist of the retinoic acid nuclear receptor gamma, which was discovered in the company’s oncology drug program. The presentation titled “RAR Gamma Agonist Compounds [...]
VICTORIA, Seychelles, Nov. 08, 2024 (Korea Bizwire) – Bitget, the leading cryptocurrency exchange and Web3 company, has released the latest valuation of its Protection Fund for October 2024. The fund, an essential safeguard for the exchange indicates the platform’s ongoing measures to secure user assets and uphold financial stability. Throughout October, the Protection Fund experienced notable [...]
– BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor microenvironment - –In preclinical models, BPT958 induces potent antitumor activity with minimal systemic activation - BASEL, Switzerland and SAN DIEGO, Nov. 08, 2024 (Korea Bizwire) – Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering [...]
First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrollment continuing Research Triangle Park, N.C., Nov. 07, 2024 (Korea Bizwire) – Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received [...]
RIYADH, Saudi Arabia, Nov. 07, 2024 (Korea Bizwire) – 20 agreements worth more than 1.35bn Saudi Riyals were signed on the second day of Biban24 forum. In line with Vision 2030, these partnerships and agreements were launched to empower Saudi Arabia’s thriving community of entrepreneurs and advance entrepreneurship in the Kingdom and beyond. Day 2 [...]
UTRECHT, The Netherlands, Nov. 07, 2024 (Korea Bizwire) – Today, ATNi launches the 5th edition of the Global Access to Nutrition Index, the largest yet, assessing the world’s 30 largest food and beverage manufacturers and over 52,000 products, representing 23% global market share. One in five deaths globally is associated with a poor diet. One out [...]
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers VANCOUVER, British Columbia, Nov. 05, 2024 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard [...]
Vancouver, Nov. 04, 2024 (Korea Bizwire) – Deutsche Aircraft, and Pratt & Whitney Canada, announce the conclusion of a series of five emission and contrail measurement flights on a D328® UpLift research aircraft using a fully synthetic Fischer-Tropsch fuel, preparing for the use of future sustainable aviation fuels (SAF) produced using Power-to-Liquid (PtL) technology. This [...]